Amitha Parvataneni, MD
Family Medicine · Saint Clair Shores, MINPI 1336326362
Payments from drug & device makers
Across 224 payments — averaging $20.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$866
- AstraZeneca$427
- Esperion Therapeutics, Inc.$417
- Novo Nordisk$382
- GSK$376
- Bayer$284
- plus $2K from 33 others
What the payments were for
- Food & beverage$4,690100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 43 | $866 |
| AstraZeneca(2 entities) | 20 | $427 |
| Esperion Therapeutics, Inc. | 19 | $417 |
| Novo Nordisk | 18 | $382 |
| GSK | 17 | $376 |
| Bayer | 5 | $284 |
| Amgen(2 entities) | 10 | $255 |
| Scilex Pharmaceuticals Inc. | 10 | $220 |
| Pfizer | 11 | $167 |
| Amarin Pharma, Inc. | 11 | $149 |
| Abbott | 3 | $140 |
| UCB, Inc. | 5 | $103 |
| Lilly USA, LLC | 4 | $79 |
| Novartis | 6 | $78 |
| Exact Sciences | 3 | $63 |
| Indivior Inc. | 3 | $49 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $47 |
| Lundbeck LLC | 2 | $44 |
| Biohaven Pharmaceuticals, Inc. | 3 | $42 |
| Otsuka America Pharmaceutical, Inc. | 2 | $37 |
| Boehringer Ingelheim | 2 | $37 |
| Johnson & Johnson | 2 | $34 |
| Merck | 2 | $33 |
| Collegium Pharmaceutical, Inc. | 2 | $31 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $31 |
| Acadia Pharmaceuticals Inc | 2 | $30 |
| Ultragenyx Pharmaceutical Inc. | 2 | $30 |
| Braeburn Inc. | 1 | $28 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $28 |
| Tonix Medicines, Inc. | 1 | $25 |
| Vanda Pharmaceuticals Inc. | 1 | $23 |
| Eisai Inc. | 1 | $22 |
| Teva Pharmaceuticals USA, Inc. | 1 | $21 |
| Avanir Pharmaceuticals, Inc. | 1 | $20 |
| Phadia US Inc. | 1 | $18 |
| Alkermes, Inc. | 1 | $17 |
| Aimmune Therapeutics, Inc. | 1 | $14 |
| Orexo US, Inc. | 1 | $14 |
| Endo Pharmaceuticals Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Kerendia$236
- TRELEGY ELLIPTA$226
- UBRELVY$207
- Repatha$126
- BREZTRI AEROSPHERE$125
- Ozempic$125
- NEXLIZET$122
- NEXLETOL$122
- FREESTYLE LIBRE 3$104
How this compares
$4,690 in reported general payments places this provider in the 90th percentile of 3,945 family medicine providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LinzessLinaclotide | 11 | $5,964 |
| Famotidine | 24 | $5,607 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 26 | $3,173 |
| Cyclobenzaprine Hcl | 42 | $1,550 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 49 | $1,502 |
| Lidocaine | 16 | $871 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 76 | $860 |
| Ventolin HfaAlbuterol Sulfate | 16 | $856 |
| Lidocaine-PrilocaineLidocaine/Prilocaine | 19 | $747 |
| Diclofenac Sodium | 29 | $658 |
| Ciclopirox | 13 | $232 |
| Rosuvastatin Calcium | 35 | $116 |
| Fluticasone Propionate | 13 | $113 |
| Hydrocortisone | 18 | $92 |
| Metformin Hcl | 47 | $91 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLinzess | $866 | $5,96411 claims |
| Lilly USA, LLCOlanzapine | $79 | $5211 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,945 family medicine providers in Michigan.
Other family medicine in Saint Clair Shores
- Derrick WilliamsonSouthfield$9.9M
- Rebecca RivardRoseville$7M
- Paul BensonBerkley$4.2M
- Michael HafranEast Lansing$2.7M
- Mitzie HewittBuckley$1.3M
- Loren ChudlerSouthfield$1.3M
- Solomon AmsterWhite Lake$981K
- Matt RosenbergJackson$559K
- Rhonda MejeurGrand Rapids$493K
- Steve LasaterSaint Johns$291K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.